Found 656 hits of Enzyme Inhibition Constant Data Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208891
(US9266878, 117a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1 |r| Show InChI InChI=1S/C25H18ClN9O/c1-15(33-23-17(22(27)31-14-32-23)8-9-20-29-11-4-12-30-20)24-34-19-7-2-6-18(26)21(19)25(36)35(24)16-5-3-10-28-13-16/h2-7,10-15H,1H3,(H3,27,31,32,33)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208892
(US9266878, 118a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1 |r| Show InChI InChI=1S/C25H18ClN9O/c1-15(33-23-18(22(27)31-14-32-23)8-7-16-12-29-10-11-30-16)24-34-20-6-2-5-19(26)21(20)25(36)35(24)17-4-3-9-28-13-17/h2-6,9-15H,1H3,(H3,27,31,32,33)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208915
(US9266878, 141a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(C)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O/c1-17-8-6-9-19(33-17)14-15-21-25(30)31-16-32-26(21)34-18(2)27-35-23-13-7-12-22(29)24(23)28(37)36(27)20-10-4-3-5-11-20/h3-13,16,18H,1-2H3,(H3,30,31,32,34)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208928
(US9266878, 154a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(CO)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O2/c1-17(34-26-21(25(30)32-16-33-26)11-10-19-14-18(15-37)12-13-31-19)27-35-23-9-5-8-22(29)24(23)28(38)36(27)20-6-3-2-4-7-20/h2-9,12-14,16-17,37H,15H2,1H3,(H3,30,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208794
(US9266878, 17a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)cc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C28H18ClF5N8O/c1-13(26-41-21-4-2-3-20(29)23(21)27(43)42(26)17-8-15(30)7-16(31)9-17)40-25-18(24(36)38-12-39-25)6-5-14-11-37-22(35)10-19(14)28(32,33)34/h2-4,7-13H,1H3,(H2,35,37)(H3,36,38,39,40)/t13-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208798
(US9266878, 23a)Show SMILES C[C@H](Nc1ncnc(N)c1C#CC1CC1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C25H19ClF2N6O/c1-13(32-23-18(8-7-14-5-6-14)22(29)30-12-31-23)24-33-20-4-2-3-19(26)21(20)25(35)34(24)17-10-15(27)9-16(28)11-17/h2-4,9-14H,5-6H2,1H3,(H3,29,30,31,32)/t13-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208811
(US9266878, 36a)Show SMILES Nc1ncnc(N2CCCC[C@H]2c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1C#Cc1ccccn1 Show InChI InChI=1S/C30H24ClN7O/c31-23-12-8-13-24-26(23)30(39)38(21-10-2-1-3-11-21)29(36-24)25-14-5-7-18-37(25)28-22(27(32)34-19-35-28)16-15-20-9-4-6-17-33-20/h1-4,6,8-13,17,19,25H,5,7,14,18H2,(H2,32,34,35)/t25-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208815
(US9266878, 40a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(c1)S(N)(=O)=O |r| Show InChI InChI=1S/C27H21ClN8O3S/c1-16(34-25-20(24(29)32-15-33-25)12-11-17-6-2-3-13-31-17)26-35-22-10-5-9-21(28)23(22)27(37)36(26)18-7-4-8-19(14-18)40(30,38)39/h2-10,13-16H,1H3,(H2,30,38,39)(H3,29,32,33,34)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208817
(US9266878, 42a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cncnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C26H19ClN8O/c1-16(33-24-19(23(28)31-15-32-24)11-10-17-12-29-14-30-13-17)25-34-21-9-5-8-20(27)22(21)26(36)35(25)18-6-3-2-4-7-18/h2-9,12-16H,1H3,(H3,28,31,32,33)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208825
(US9266878, 50a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H20ClN7O/c1-17(33-25-20(24(29)31-16-32-25)14-13-18-8-5-6-15-30-18)26-34-22-12-7-11-21(28)23(22)27(36)35(26)19-9-3-2-4-10-19/h2-12,15-17H,1H3,(H3,29,31,32,33)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208840
(US9266878, 65a)Show SMILES COc1cc(F)cc(c1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H22F2N6O2/c1-17(28-36-24-10-6-9-23(31)25(24)29(38)37(28)20-7-4-3-5-8-20)35-27-22(26(32)33-16-34-27)12-11-18-13-19(30)15-21(14-18)39-2/h3-10,13-17H,1-2H3,(H3,32,33,34,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208845
(US9266878, 70a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cccc(c1)C#N |r| Show InChI InChI=1S/C29H19F3N8O/c1-16(38-27-22(26(34)36-15-37-27)11-10-19-9-8-18(30)14-35-19)28-39-23-7-3-6-21(25(31)32)24(23)29(41)40(28)20-5-2-4-17(12-20)13-33/h2-9,12,14-16,25H,1H3,(H3,34,36,37,38)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208880
(US9266878, 106a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(C)c2c(=O)n1-c1cccc(F)c1 |r| Show InChI InChI=1S/C27H21FN8O/c1-16-5-3-8-22-23(16)27(37)36(20-7-4-6-18(28)13-20)26(35-22)17(2)34-25-21(24(29)32-15-33-25)10-9-19-14-30-11-12-31-19/h3-8,11-15,17H,1-2H3,(H3,29,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208883
(US9266878, 109a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C26H19FN8O/c1-16(33-24-18(23(28)31-15-32-24)11-12-21-29-13-6-14-30-21)25-34-20-10-5-9-19(27)22(20)26(36)35(25)17-7-3-2-4-8-17/h2-10,13-16H,1H3,(H3,28,31,32,33)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208902
(US9266878, 128a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C)c2c(=O)n1-c1cccc(CN(C)S(C)(=O)=O)c1 |r| Show InChI InChI=1S/C31H29FN8O3S/c1-19-7-5-10-26-27(19)31(41)40(24-9-6-8-21(15-24)17-39(3)44(4,42)43)30(38-26)20(2)37-29-25(28(33)35-18-36-29)14-13-23-12-11-22(32)16-34-23/h5-12,15-16,18,20H,17H2,1-4H3,(H3,33,35,36,37)/t20-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208908
(US9266878, 134a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(cn1)C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C28H17ClF5N7O/c1-14(39-25-20(24(35)37-13-38-25)8-7-18-6-5-15(12-36-18)28(32,33)34)26-40-22-4-2-3-21(29)23(22)27(42)41(26)19-10-16(30)9-17(31)11-19/h2-6,9-14H,1H3,(H3,35,37,38,39)/t14-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208917
(US9266878, 143a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O/c1-17-8-7-15-31-22(17)14-13-20-25(30)32-16-33-26(20)34-18(2)27-35-23-12-6-11-21(29)24(23)28(37)36(27)19-9-4-3-5-10-19/h3-12,15-16,18H,1-2H3,(H3,30,32,33,34)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208922
(US9266878, 148a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(ccn1)C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H19ClF3N7O/c1-16(26-38-22-9-5-8-21(29)23(22)27(40)39(26)19-6-3-2-4-7-19)37-25-20(24(33)35-15-36-25)11-10-18-14-17(12-13-34-18)28(30,31)32/h2-9,12-16H,1H3,(H3,33,35,36,37)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208925
(US9266878, 151a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(n1)C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H19ClF3N7O/c1-16(26-38-21-11-6-10-20(29)23(21)27(40)39(26)18-8-3-2-4-9-18)36-25-19(24(33)34-15-35-25)14-13-17-7-5-12-22(37-17)28(30,31)32/h2-12,15-16H,1H3,(H3,33,34,35,36)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208928
(US9266878, 154a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(CO)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O2/c1-17(34-26-21(25(30)32-16-33-26)11-10-19-14-18(15-37)12-13-31-19)27-35-23-9-5-8-22(29)24(23)28(38)36(27)20-6-3-2-4-7-20/h2-9,12-14,16-17,37H,15H2,1H3,(H3,30,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208930
(US9266878, 156a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(ccn1)C(N)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClN8O2/c1-16(27-36-22-9-5-8-21(29)23(22)28(39)37(27)19-6-3-2-4-7-19)35-26-20(24(30)33-15-34-26)11-10-18-14-17(25(31)38)12-13-32-18/h2-9,12-16H,1H3,(H2,31,38)(H3,30,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208778
(US9266878, 1a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(F)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C27H16F5N7O/c1-13(37-25-19(24(33)35-12-36-25)5-4-17-3-2-14(28)11-34-17)26-38-23-21(32)7-6-20(31)22(23)27(40)39(26)18-9-15(29)8-16(30)10-18/h2-3,6-13H,1H3,(H3,33,35,36,37)/t13-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208790
(US9266878, 13a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)cccc2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H19F2N7O/c1-16(34-25-21(24(30)32-15-33-25)13-12-18-11-10-17(28)14-31-18)26-35-23-20(8-5-9-22(23)29)27(37)36(26)19-6-3-2-4-7-19/h2-11,14-16H,1H3,(H3,30,32,33,34)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208812
(US9266878, 37a)Show SMILES Nc1ncnc(N2CCC[C@H]2c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1C#Cc1ccccn1 |r| Show InChI InChI=1S/C29H22ClN7O/c30-22-11-6-12-23-25(22)29(38)37(20-9-2-1-3-10-20)28(35-23)24-13-7-17-36(24)27-21(26(31)33-18-34-27)15-14-19-8-4-5-16-32-19/h1-6,8-12,16,18,24H,7,13,17H2,(H2,31,33,34)/t24-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208825
(US9266878, 50a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H20ClN7O/c1-17(33-25-20(24(29)31-16-32-25)14-13-18-8-5-6-15-30-18)26-34-22-12-7-11-21(28)23(22)27(36)35(26)19-9-3-2-4-10-19/h2-12,15-17H,1H3,(H3,29,31,32,33)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208838
(US9266878, 63a)Show SMILES COc1cc(F)cc(c1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2c(F)ccc(F)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H21F3N6O2/c1-16(36-27-21(26(33)34-15-35-27)9-8-17-12-18(30)14-20(13-17)40-2)28-37-25-23(32)11-10-22(31)24(25)29(39)38(28)19-6-4-3-5-7-19/h3-7,10-16H,1-2H3,(H3,33,34,35,36)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208852
(US9266878, 77a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(C(F)F)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C28H18F5N7O/c1-14(38-26-21(25(34)36-13-37-26)8-7-18-6-5-15(29)12-35-18)27-39-22-4-2-3-20(24(32)33)23(22)28(41)40(27)19-10-16(30)9-17(31)11-19/h2-6,9-14,24H,1H3,(H3,34,36,37,38)/t14-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208865
(US9266878, 91a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C26H19FN8O/c1-16(33-24-20(23(28)31-15-32-24)9-8-18-14-29-11-12-30-18)25-34-22-10-7-17(27)13-21(22)26(36)35(25)19-5-3-2-4-6-19/h2-7,10-16H,1H3,(H3,28,31,32,33)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208868
(US9266878, 94a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(c1)C#N |r| Show InChI InChI=1S/C28H18F2N8O/c1-16(36-26-22(25(32)34-15-35-26)9-8-20-7-5-19(30)14-33-20)27-37-24-10-6-18(29)12-23(24)28(39)38(27)21-4-2-3-17(11-21)13-31/h2-7,10-12,14-16H,1H3,(H3,32,34,35,36)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208915
(US9266878, 141a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(C)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O/c1-17-8-6-9-19(33-17)14-15-21-25(30)31-16-32-26(21)34-18(2)27-35-23-13-7-12-22(29)24(23)28(37)36(27)20-10-4-3-5-11-20/h3-13,16,18H,1-2H3,(H3,30,31,32,34)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208917
(US9266878, 143a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O/c1-17-8-7-15-31-22(17)14-13-20-25(30)32-16-33-26(20)34-18(2)27-35-23-12-6-11-21(29)24(23)28(37)36(27)19-9-4-3-5-10-19/h3-12,15-16,18H,1-2H3,(H3,30,32,33,34)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208789
(US9266878, 12a)Show SMILES COc1ccc(nc1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2c(F)cccc2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22FN7O2/c1-17(34-26-22(25(30)32-16-33-26)14-12-18-11-13-20(38-2)15-31-18)27-35-24-21(9-6-10-23(24)29)28(37)36(27)19-7-4-3-5-8-19/h3-11,13,15-17H,1-2H3,(H3,30,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208801
(US9266878, 26a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(OC(F)(F)F)cc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C29H18ClF5N6O2/c1-15(27-40-23-4-2-3-22(30)24(23)28(42)41(27)19-12-17(31)11-18(32)13-19)39-26-21(25(36)37-14-38-26)10-7-16-5-8-20(9-6-16)43-29(33,34)35/h2-6,8-9,11-15H,1H3,(H3,36,37,38,39)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208803
(US9266878, 28a)Show SMILES C[C@H](Nc1ncnc(N)c1C#CC(C)(C)O)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C25H21ClF2N6O2/c1-13(32-22-17(7-8-25(2,3)36)21(29)30-12-31-22)23-33-19-6-4-5-18(26)20(19)24(35)34(23)16-10-14(27)9-15(28)11-16/h4-6,9-13,36H,1-3H3,(H3,29,30,31,32)/t13-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208847
(US9266878, 72a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(C)c2c(=O)n1-c1cccc(c1)C#N |r| Show InChI InChI=1S/C29H20F2N8O/c1-16-6-11-23(31)25-24(16)29(40)39(21-5-3-4-18(12-21)13-32)28(38-25)17(2)37-27-22(26(33)35-15-36-27)10-9-20-8-7-19(30)14-34-20/h3-8,11-12,14-15,17H,1-2H3,(H3,33,35,36,37)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208859
(US9266878, 84a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C27H16ClF4N7O/c1-13(37-25-19(24(33)35-12-36-25)5-4-17-3-2-14(29)11-34-17)26-38-23-21(32)7-6-20(28)22(23)27(40)39(26)18-9-15(30)8-16(31)10-18/h2-3,6-13H,1H3,(H3,33,35,36,37)/t13-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208904
(US9266878, 130a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(CNS(C)(=O)=O)c1 |r| Show InChI InChI=1S/C29H24ClFN8O3S/c1-17(37-27-22(26(32)34-16-35-27)12-11-20-10-9-19(31)15-33-20)28-38-24-8-4-7-23(30)25(24)29(40)39(28)21-6-3-5-18(13-21)14-36-43(2,41)42/h3-10,13,15-17,36H,14H2,1-2H3,(H3,32,34,35,37)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208909
(US9266878, 135a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(cn1)C(N)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClN8O2/c1-16(27-36-22-9-5-8-21(29)23(22)28(39)37(27)19-6-3-2-4-7-19)35-26-20(24(30)33-15-34-26)13-12-18-11-10-17(14-32-18)25(31)38/h2-11,14-16H,1H3,(H2,31,38)(H3,30,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208935
(US9266878, 161a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(c1)C(C)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C30H23ClN6O2/c1-18(29-36-25-13-7-12-24(31)26(25)30(39)37(29)22-10-4-3-5-11-22)35-28-23(27(32)33-17-34-28)15-14-20-8-6-9-21(16-20)19(2)38/h3-13,16-18H,1-2H3,(H3,32,33,34,35)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208780
(US9266878, 3a)Show SMILES COC(=O)c1ccc(nc1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H22ClN7O3/c1-17(27-36-23-10-6-9-22(30)24(23)28(38)37(27)20-7-4-3-5-8-20)35-26-21(25(31)33-16-34-26)14-13-19-12-11-18(15-32-19)29(39)40-2/h3-12,15-17H,1-2H3,(H3,31,33,34,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208785
(US9266878, 8a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H19F2N7O/c1-16(34-25-20(24(30)32-15-33-25)13-12-18-11-10-17(28)14-31-18)26-35-22-9-5-8-21(29)23(22)27(37)36(26)19-6-3-2-4-7-19/h2-11,14-16H,1H3,(H3,30,32,33,34)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208796
(US9266878, 19b)Show SMILES CC(O)C#Cc1c(N)ncnc1N[C@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C24H21ClN6O2/c1-14(32)11-12-17-21(26)27-13-28-22(17)29-15(2)23-30-19-10-6-9-18(25)20(19)24(33)31(23)16-7-4-3-5-8-16/h3-10,13-15,32H,1-2H3,(H3,26,27,28,29)/t14?,15-/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208811
(US9266878, 36a)Show SMILES Nc1ncnc(N2CCCC[C@H]2c2nc3cccc(Cl)c3c(=O)n2-c2ccccc2)c1C#Cc1ccccn1 Show InChI InChI=1S/C30H24ClN7O/c31-23-12-8-13-24-26(23)30(39)38(21-10-2-1-3-11-21)29(36-24)25-14-5-7-18-37(25)28-22(27(32)34-19-35-28)16-15-20-9-4-6-17-33-20/h1-4,6,8-13,17,19,25H,5,7,14,18H2,(H2,32,34,35)/t25-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208813
(US10221197, Compound 37 | US9266878, 38a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(c1)C(N)=O |r| Show InChI InChI=1S/C28H21ClN8O2/c1-16(35-26-20(24(30)33-15-34-26)12-11-18-7-2-3-13-32-18)27-36-22-10-5-9-21(29)23(22)28(39)37(27)19-8-4-6-17(14-19)25(31)38/h2-10,13-16H,1H3,(H2,31,38)(H3,30,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208819
(US9266878, 44a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H20ClN7O/c1-17(33-25-20(24(29)31-16-32-25)13-12-18-7-6-14-30-15-18)26-34-22-11-5-10-21(28)23(22)27(36)35(26)19-8-3-2-4-9-19/h2-11,14-17H,1H3,(H3,29,31,32,33)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
(Homo sapiens (Human)) | BDBM208826
(US9266878, 51a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClN6O/c1-18(33-26-21(25(30)31-17-32-26)16-15-19-9-4-2-5-10-19)27-34-23-14-8-13-22(29)24(23)28(36)35(27)20-11-6-3-7-12-20/h2-14,17-18H,1H3,(H3,30,31,32,33)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208787
(US9266878, 10a)Show SMILES COc1ccc(nc1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2c(Cl)ccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21Cl2N7O2/c1-16(35-26-20(25(31)33-15-34-26)11-9-17-8-10-19(39-2)14-32-17)27-36-24-22(30)13-12-21(29)23(24)28(38)37(27)18-6-4-3-5-7-18/h3-8,10,12-16H,1-2H3,(H3,31,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208780
(US9266878, 3a)Show SMILES COC(=O)c1ccc(nc1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H22ClN7O3/c1-17(27-36-23-10-6-9-22(30)24(23)28(38)37(27)20-7-4-3-5-8-20)35-26-21(25(31)33-16-34-26)14-13-19-12-11-18(15-32-19)29(39)40-2/h3-12,15-17H,1-2H3,(H3,31,33,34,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208800
(US9266878, 25a)Show SMILES C[C@H](Nc1nc(N)nc(N)c1C#Cc1ccccc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O/c1-17(32-25-20(24(30)34-28(31)35-25)16-15-18-9-4-2-5-10-18)26-33-22-14-8-13-21(29)23(22)27(37)36(26)19-11-6-3-7-12-19/h2-14,17H,1H3,(H5,30,31,32,34,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208802
(US9266878, 27a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(OC(F)(F)F)cc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H20ClF3N6O2/c1-17(27-38-23-9-5-8-22(30)24(23)28(40)39(27)19-6-3-2-4-7-19)37-26-21(25(34)35-16-36-26)15-12-18-10-13-20(14-11-18)41-29(31,32)33/h2-11,13-14,16-17H,1H3,(H3,34,35,36,37)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 550 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Search and Browse
